FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Marc Cohen

Research Profile

Chemicals & Drugs

Disorders

Concepts & Ideas

Procedures

Phenomena

Recurrence

Co-author Network

Publications

TOP 3
Michael P Thomas; Elliott M Antman; Robert M Califf; Karen Chiswell; Marc Cohen; James J Ferguson; Shaun G Goodman; Michael C Kontos; Kenneth W Mahaffey; Richard C Becker
Activated partial thromboplastin time measurement is not associated with clinical outcomes in patients with high-risk non-ST-segment elevation acute coronary syndromes treated with unfractionated heparin.
Manesh R Patel; Divaka Perera; Richard W Smalling; Holger Thiele; Yi Zhou; Huiman X Barnhart; Praveen Chandra; Derek Chew; Marc Cohen; John French; E Magnus Ohman
Intra-aortic balloon counterpulsation and infarct size in patients with acute anterior myocardial infarction without shock: the CRISP AMI randomized trial.
Manesh R Patel; Divaka Perera; Richard W Smalling; Holger Thiele; Yi Zhou; Praveen Chandra; Marc Cohen; Erik Magnus Ohman
A multicenter, randomized, controlled study of mechanical left ventricular unloading with counterpulsation to reduce infarct size prepercutaneous coronary intervention for acute myocardial infarction: rationale and design of the Counterpulsation Reduces Infarct Size Acute Myocardial Infarction trial.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Marc Cohen (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Michael P Thomas; Elliott M Antman; Robert M Califf; Karen Chiswell; Marc Cohen; James J Ferguson; Shaun G Goodman; Michael C Kontos; Kenneth W Mahaffey; Richard C Becker
Activated partial thromboplastin time measurement is not associated with clinical outcomes in patients with high-risk non-ST-segment elevation acute coronary syndromes treated with unfractionated heparin.
Journal of thrombosis and thrombolysis 2012;34(1):114-9.
2011: Manesh R Patel; Divaka Perera; Richard W Smalling; Holger Thiele; Yi Zhou; Huiman X Barnhart; Praveen Chandra; Derek Chew; Marc Cohen; John French; E Magnus Ohman
Intra-aortic balloon counterpulsation and infarct size in patients with acute anterior myocardial infarction without shock: the CRISP AMI randomized trial.
JAMA : the journal of the American Medical Association 2011;306(12):1329-37.
2011: Manesh R Patel; Divaka Perera; Richard W Smalling; Holger Thiele; Yi Zhou; Praveen Chandra; Marc Cohen; Erik Magnus Ohman
A multicenter, randomized, controlled study of mechanical left ventricular unloading with counterpulsation to reduce infarct size prepercutaneous coronary intervention for acute myocardial infarction: rationale and design of the Counterpulsation Reduces Infarct Size Acute Myocardial Infarction trial.
American heart journal 2011;162(1):47-55.e1.
2011: Robert P Giugliano; Charles V Pollack; Gerard X Brogan; Marc Cohen; Deborah B Diercks; Cindy L Grines; Timothy D Henry; Neal S Kleiman
Acute coronary syndromes: from the emergency department to the catheterization laboratory-integrating evidence from recent ACS/NSTEMI trials into clinical practice: an evidence-based review of recent clinical trial results and report on a roundtable discussion.
Journal of interventional cardiology 2011;24(2):119-36.
2011: Kenneth W Mahaffey; Karen S Pieper; Yuliya Lokhnygina; Robert M Califf; Elliott M Antman; Neal S Kleiman; Shaun G Goodman; Harvey D White; Sunil V Rao; Judith S Hochman; Marc Cohen; Jacques J Col; Matthew T Roe; James J Ferguson
The impact of postrandomization crossover of therapy in acute coronary syndromes care.
Circulation. Cardiovascular quality and outcomes 2011;4(2):211-9.
2011: David A Baran; Mark J Zucker; Luis H Arroyo; Margarita Camacho; Marc E Goldschmidt; Stephen J Nicholls; Jeanne Prevost-Fernandez; Candace Carr; Laura Adams; Susan Pardi; Vera Hou; Maria Binetti; Jeanine McCahill; Joanne Chichetti; Valerie Viloria; Mary Gladys Sanagustin; Jennifer Ebuenga-Smith; Leslie Mele; Anthony Martin; Donna Blicharz; Kathy Wolski; Ludmilla Olesnicky; Fang Qian; Alan L Gass; Marc Cohen
A prospective, randomized trial of single-drug versus dual-drug immunosuppression in heart transplantation: the tacrolimus in combination, tacrolimus alone compared (TICTAC) trial.
Circulation. Heart failure 2011;4(2):129-37.
2010: Deepak L Bhatt; Byron L Cryer; Charles F Contant; Marc Cohen; Angel Lanas; Thomas J Schnitzer; Thomas L Shook; Pablo Lapuerta; Mark A Goldsmith; Loren Laine; Benjamin M Scirica; Sabina A Murphy; Christopher P Cannon
Clopidogrel with or without omeprazole in coronary artery disease.
The New England journal of medicine 2010;363(20):1909-17.
2010: Sargis Khoobiar; Aaron Vanhise; Renato Apolito; Marc Cohen
Interatrial thrombus-in-transit resulting in paradoxical thromboembolism.
Journal of thrombosis and thrombolysis 2010;29(1):127-9.
2009: Marc Cohen
Antiplatelet therapy in percutaneous coronary intervention: a critical review of the 2007 AHA/ACC/SCAI guidelines and beyond.
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 2009;74(4):579-97.
2009: Marc Cohen
Expanding the recognition and assessment of bleeding events associated with antiplatelet therapy in primary care.
Mayo Clinic proceedings. Mayo Clinic 2009;84(2):149-60.
2008: Marc Cohen; James Hoekstra
The use of adjunctive anticoagulants in patients with acute coronary syndrome transitioning to percutaneous coronary intervention.
The American journal of emergency medicine 2008;26(8):932-41.
2008: Marc Cohen
High-risk acute coronary syndrome patients with non-ST-elevation myocardial infarction: definition and treatment.
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 2008;22(5):407-18.
2008: Marc Cohen; Gerald V Naccarelli
Pathophysiology and disease progression of atrial fibrillation: importance of achieving and maintaining sinus rhythm.
Journal of cardiovascular electrophysiology 2008;19(8):885-90.
2008: Kenneth W Mahaffey; Qinghong Yang; Karen S Pieper; Elliott M Antman; Harvey D White; Shaun G Goodman; Marc Cohen; Neal S Kleiman; Anatoly Langer; Philip E G Aylward; Jacques J Col; Craig J Reist; James J Ferguson; Robert M Califf
Prediction of one-year survival in high-risk patients with acute coronary syndromes: results from the SYNERGY trial.
Journal of general internal medicine 2008;23(3):310-6.
2007: Sabina A Murphy; Charles Michael Gibson; David A Morrow; Frans Van de Werf; Ian B Menown; Shaun G Goodman; Kenneth W Mahaffey; Marc Cohen; Carolyn H McCabe; Elliott M Antman; Eugene Braunwald
Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis.
European heart journal 2007;28(17):2077-86.
2007: C Michael Gibson; Sabina A Murphy; Gilles Montalescot; David A Morrow; Diego Ardissino; Marc Cohen; Dietrich C Gulba; Oscar H Kracoff; Basil S. Lewis; Nathan Roguin; Elliott M Antman; Eugene Braunwald
Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trial.
Journal of the American College of Cardiology 2007;49(23):2238-46.
2007: Warren J Cantor; Kenneth W Mahaffey; Zhen Huang; Pranab Das; Dietrich C Gulba; Stanislav Glezer; Richard Gallo; John Ducas; Marc Cohen; Elliott M Antman; Anatoly Langer; Neal S Kleiman; Harvey D White; Robert J Chisholm; Robert A Harrington; James J Ferguson; Robert M Califf; Shaun G Goodman
Bleeding complications in patients with acute coronary syndrome undergoing early invasive management can be reduced with radial access, smaller sheath sizes, and timely sheath removal.
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 2007;69(1):73-83.
2006: Harvey D White; Neal S Kleiman; Kenneth W Mahaffey; Yuliya Lokhnygina; Karen S Pieper; Karen Chiswell; Marc Cohen; Robert A Harrington; Derek P Chew; John L Petersen; Lisa G Berdan; Philip E G Aylward; Christopher C. Nessel; James J Ferguson; Robert M Califf
Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial.
American heart journal 2006;152(6):1042-50.
2006: Shaun G Goodman; Gerardo E Bozovich; Mary Tan; Alfonso Dos Santos; Enrique P Gurfinkel; Marc Cohen; Anatoly Langer
The greatest benefit of enoxaparin over unfractionated heparin in acute coronary syndromes is achieved in patients presenting with ST-segment changes: the Enoxaparin in Non-Q-Wave Coronary Events (ESSENCE) Electrocardiogram Core Laboratory Substudy.
American heart journal 2006;151(4):791-7.
2006: Marc Cohen; Debbie Singh
At six months, enoxaparin is more effective than tinzaparin for people with non ST-segment elevation acute coronary syndromes.
Evidence-based cardiovascular medicine 2006;10(1):30-1.
2005: Kenneth W Mahaffey; Marc Cohen; Jyotsna Garg; Elliott M Antman; Neal S Kleiman; Shaun G Goodman; Lisa G Berdan; Craig J Reist; Anatoly Langer; Harvey D White; Philip E G Aylward; Jacques J Col; James J Ferguson; Robert M Califf
High-risk patients with acute coronary syndromes treated with low-molecular-weight or unfractionated heparin: outcomes at 6 months and 1 year in the SYNERGY trial.
JAMA : the journal of the American Medical Association 2005;294(20):2594-600.
2005: Marc Cohen; Andrea Alberto Conti; Frans Maritz; Enrique P Gurfinkel; Kurt Huber; Ari Timerman; Jose Santopinto; Giancarlo Corsini; Pierfranco Terrosu; Florence Joulain
The role of gender and other factors as predictors of not receiving reperfusion therapy and of outcome in ST-segment elevation myocardial infarction.
Journal of thrombosis and thrombolysis 2005;19(3):155-61.
2005: Marc Cohen
Predictors of bleeding risk and long-term mortality in patients with acute coronary syndromes.
Current medical research and opinion 2005;21(3):439-45.
2004: John L Petersen; Kenneth W Mahaffey; Richard C Becker; Shaun G Goodman; Neal S Kleiman; A J Marian; Gregg W Stone; Alexandra J Lansky; A Michael Lincoff; Stanley L Hazen; Christopher C. Nessel; Luis Toro-Figueroa; Lynn Tate; Craig J Reist; Marc Cohen; Robert M Califf; James J Ferguson
Coordinated series of studies to evaluate characteristics and mechanisms of acute coronary syndromes in high-risk patients randomly assigned to enoxaparin or unfractionated heparin: design and rationale of the SYNERGY Library.
American heart journal 2004;148(2):269-76.
2004: John L Petersen; Kenneth W Mahaffey; Vic Hasselblad; Elliott M Antman; Marc Cohen; Shaun G Goodman; Anatoly Langer; Michael A Blazing; Anne Le-Moigne-Amrani; James A de Lemos; Christopher C. Nessel; Robert A Harrington; James J Ferguson; Eugene Braunwald; Robert M Califf
Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview.
JAMA : the journal of the American Medical Association 2004;292(1):89-96.
2003: Marc Cohen; Andrea Alberto Conti; Frans Maritz; Enrique P Gurfinkel; Kurt Huber; Ari Timerman; Maria Krzeminska-Pakula; Jose Santopinto; Carole Hecquet; Luc Vittori
Prospective evaluation of clinical outcomes after acute ST-elevation myocardial infarction in patients who are ineligible for reperfusion therapy: preliminary results from the TETAMI registry and randomized trial.
Circulation 2003;108(16 Suppl 1):III14-21.
2003: Marc Cohen; Andrea Alberto Conti; Frans Maritz; Enrique P Gurfinkel; Kurt Huber; Ari Timerman; Maria Krzeminska-Pakula; Nicolas Danchin; Harvey D White; Jose Santopinto; Frederique Bigonzi; Carole Hecquet; Luc Vittori
The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial.
Journal of the American College of Cardiology 2003;42(8):1348-56.
2002: Marc Cohen; Pierre Théroux; Steven Borzak; Martin J Frey; Harvey D White; W Van Mieghem; Fred Senatore; Joy Lis; Robin Mukherjee; Kathy Harris; Frederique Bigonzi
Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study. The Antithrombotic Combination Using Tirofiban and Enoxaparin.
American heart journal 2002;144(3):470-7.
2002: Keith A A Fox; Elliott M Antman; Marc Cohen; Frederique Bigonzi
Comparison of enoxaparin versus unfractionated heparin in patients with unstable angina pectoris/non-ST-segment elevation acute myocardial infarction having subsequent percutaneous coronary intervention.
The American journal of cardiology 2002;90(5):477-82.
2002: Marc S Sabatine; Carolyn H McCabe; David A Morrow; Robert P Giugliano; James A de Lemos; Marc Cohen; Elliott M Antman; Eugene Braunwald
Identification of patients at high risk for death and cardiac ischemic events after hospital discharge.
American heart journal 2002;143(6):966-70.
2002: Marc Cohen; Elliott M Antman
Superiority of enoxaparin over unfractionated heparin for the treatment of acute coronary syndromes.
Pharmacotherapy 2002;22(4):542-6; author reply 546-50.
2002: Elliott M Antman; Marc Cohen; Carolyn McCabe; S G Goodman; Sabina A Murphy; Eugene Braunwald
Enoxaparin is superior to unfractionated heparin for preventing clinical events at 1-year follow-up of TIMI 11B and ESSENCE.
European heart journal 2002;23(4):308-14.
2002: Marc Cohen; Elliott M Antman; Sabina A Murphy; David Radley
Mode and timing of treatment failure (recurrent ischemic events) after hospital admission for non-ST segment elevation acute coronary syndromes.
American heart journal 2002;143(1):63-9.
2001: Marc Cohen; Elliott M Antman; Enrique P Gurfinkel; David Radley
Enoxaparin in unstable angina/non-ST-segment elevation myocardial infarction: treatment benefits in prespecified subgroups.
Journal of thrombosis and thrombolysis 2001;12(3):199-206.
2001: Scott Darrell Berkowitz; Sandra S Stinnett; Marc Cohen; GJ Fromell; Frederique Bigonzi
Prospective comparison of hemorrhagic complications after treatment with enoxaparin versus unfractionated heparin for unstable angina pectoris or non-ST-segment elevation acute myocardial infarction.
The American journal of cardiology 2001;88(11):1230-4.
2001: N de Kleer; Marc Cohen; John Semple; Andrew E Simor; Oleh Antonyshyn
Nipple piercing may be contraindicated in male patients with chest implants.
Annals of plastic surgery 2001;47(2):188-90.
2000: Marc Cohen
Calming the plaque to delay intervention for 24 hours in acute coronary syndromes.
The American journal of cardiology 2000;86(12B):18M-26M.
2000: Marc Cohen; Frans Maritz; Andrea Alberto Conti; N Danchin; Ari Timerman; Kurt Huber; Enrique P Gurfinkel; H White; Keith A A Fox; Luc Vittori; V Le Louer; Frederique Bigonzi
The TETAMI trial: the safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and of tirofiban versus placebo in the treatment of acute myocardial infarction for patients not thrombolyzed: methods and design.
Journal of thrombosis and thrombolysis 2000;10(3):241-6.
2000: Shaun G Goodman; Aiala Barr; A Sobtchouk; Marc Cohen; GJ Fromell; L Laperrière; C Hill; Anatoly Langer
Low molecular weight heparin decreases rebound ischemia in unstable angina or non-Q-wave myocardial infarction: the Canadian ESSENCE ST segment monitoring substudy.
Journal of the American College of Cardiology 2000;36(5):1507-13.
2000: Marc Cohen; Elliott M Antman; Enrique P Gurfinkel; Alexander G G Turpie; J Furst; Frederique Bigonzi; David Radley
Impact of enoxaparin low molecular weight heparin in patients with Q-wave myocardial infarction.
The American journal of cardiology 2000;86(5):553-6, A9.
2000: Shaun G Goodman; Marc Cohen; Frederique Bigonzi; Enrique P Gurfinkel; David Radley; V Le Iouer; GJ Fromell; C Demers; Alexander G G Turpie; Robert M Califf; Keith A A Fox; Anatoly Langer
Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: one-year results of the ESSENCE Study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events.
Journal of the American College of Cardiology 2000;36(3):693-8.
2000: Keith A A Fox; S Goodman; Frederique Bigonzi; V Le Louer; Marc Cohen
Inter-regional differences and outcome in unstable angina; analysis of the international ESSENCE trial. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-wave Coronary Events.
European heart journal 2000;21(17):1433-9.
2000: Elliott M Antman; Marc Cohen; PJ Bernink; Carolyn H McCabe; T Horacek; G Papuchis; Branco Mautner; R Corbalan; David Radley; Eugene Braunwald
The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making.
JAMA : the journal of the American Medical Association 2000;284(7):835-42.
2000: Marc Cohen; Sandra S Stinnett; B D Weatherley; Enrique P Gurfinkel; GJ Fromell; Shaun G Goodman; Keith A A Fox; Robert M Califf
Predictors of recurrent ischemic events and death in unstable coronary artery disease after treatment with combination antithrombotic therapy.
American heart journal 2000;139(6):962-70.
1999: Marc Cohen; Pierre Théroux; S Weber; P Laramée; thao huynh; Steven Borzak; Jean G Diodati; I B Squire; LI Deckelbaum; A R Thornton; K E Harris; FL Sax; M W Lo; H D White
Combination therapy with tirofiban and enoxaparin in acute coronary syndromes.
International journal of cardiology 1999;71(3):273-81.
1999: Elliott M Antman; Marc Cohen; David Radley; Carolyn McCabe; J Rush; J Premmereur; Eugene Braunwald
Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis.
Circulation 1999;100(15):1602-8.
1999: Enrique P Gurfinkel; Ernesto Duronto; Cecilia Colorio; Gerardo E Bozovich; Marc Cohen; Branco Mautner
Thrombotic reactant markers in non-ST segment elevation acute coronary syndromes treated with either enoxaparin (low molecular weight heparin) or unfractionated heparin.
Journal of thrombosis and thrombolysis 1999;8(3):227-32.
1998: Marc Cohen; C Demers; Enrique P Gurfinkel; Alexander G G Turpie; GJ Fromell; S Goodman; Anatoly Langer; Robert M Califf; Keith A A Fox; J Premmereur; Frederique Bigonzi
Low-molecular-weight heparins in non-ST-segment elevation ischemia: the ESSENCE trial. Efficacy and Safety of Subcutaneous Enoxaparin versus intravenous unfractionated heparin, in non-Q-wave Coronary Events.
The American journal of cardiology 1998;82(5B):19L-24L.
1998: Daniel B Mark; Patricia A Cowper; Scott Darrell Berkowitz; Linda Davidson-Ray; Elizabeth R DeLong; Alexander G G Turpie; Robert M Califf; Beth D Weatherley; Marc Cohen
Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Events [unstable angina or non-Q-wave myocardial infarction].
Circulation 1998;97(17):1702-7.
1997: Marc Cohen; C Demers; Enrique P Gurfinkel; Alexander G G Turpie; GJ Fromell; S Goodman; Anatoly Langer; Robert M Califf; Keith A A Fox; J Premmereur; Frederique Bigonzi
A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.
The New England journal of medicine 1997;337(7):447-52.
1997: Eyal Gur; Peter C Neligan; Raphael Shafir; R Reznick; Marc Cohen; Thomas Shpitzer
Squamous cell carcinoma in perineal inflammatory disease.
Annals of plastic surgery 1997;38(6):653-7.